Taken together, our data suggest that the IKBKE inhibitor CYT387 can repress RCC cell growth and enhance sunitinib sensitivity, indicating that such drugs have the potential to treat RCC patients, especially RCC patients who are resistant to sunitinib. This evidence concerns the gene IKBKE and renal cell carcinoma.